Stockreport

uniQure Publishes Data Further Demonstrating Favorable Immunogenicity Profile and Broad Utilization of AAV5-Based Gene Therapies

uniQure N.V. - Ordinary Shares  (QURE) 
Last uniqure n.v. - ordinary shares earnings: 4/29 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: uniqure.com/investors-newsroom/overview.php
PDF -- Study published in Molecular Therapy provides proof of concept of successful cross-administration of AAV5- and AAV1-based gene therapies -- LEXINGTON, Mass. and AMST [Read more]